Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
GHRP-2 (GHRP2) is a growth hormone peptide, at the clinical trials stage in the published literature. Growth Hormone Releasing Peptide-2, a potent synthetic ghrelin mimetic that strongly stimulates GH release from the pituitary gland.
Growth Hormone Releasing Peptide-2, a potent synthetic ghrelin mimetic that strongly stimulates GH release from the pituitary gland.
| Research Status | Clinical trials |
|---|---|
| Half-Life | 15-30 minutes |
| Administration | Subcutaneous injection |
| Doses Reported in Published Studies | 100-300 mcg |
Ghrelin receptor agonist that triggers GH release. Also slightly increases cortisol and prolactin.
Growth Hormone Releasing Peptide-2, a potent synthetic ghrelin mimetic that strongly stimulates GH release from the pituitary gland.
Ghrelin receptor agonist that triggers GH release. Also slightly increases cortisol and prolactin.
GHRP-2 is at the following stage in the published literature: Clinical trials. All information is for research and educational purposes only.
Reported half-life: 15-30 minutes.
Reported administration route in the literature: Subcutaneous injection. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.